Table 2.

Impact of ANG (1-7)-mas receptor blockade on ANG II-induced alterations in renal T cells in male and female SD

	Male		Female
	ANG II	ANG II + A-779	ANG II	ANG II + A-779
CD3+, % total lymphocytes	19.4 ± 0.5	19.8 ± 0.9	16.6 ± 0.2*	14.5 ± 0.5†
CD4+, % CD3+ cells	45.6 ± 0.7	43.5 ± 0.9	42.6 ± 1.0*	41.3 ± 1.0
CD44+, % CD3+CD4+ cells	50.8 ± 1.0	53.5 ± 1.3	35.8 ± 1.0*	38.5 ± 1.6†
CD69+, % CD3+CD4+ cells	10.2 ± 0.4	10.0 ± 0.4	19.4 ± 1.1*	20.3 ± 0.5†
Th17 cells, % CD3+CD4+ cells	9.2 ± 0.4	10.5 ± 0.7	5.8 ± 0.5*	6.3 ± 0.8†
Treg, % CD3+CD4+ cell	4.6 ± 0.2	3.5 ± 0.3	7.8 ± 0.7*	8.5 ± 0.9†
IL-17, % CD3+ cells	6.0 ± 0.3	5.5 ± 0.9	2.6 ± 0.2*	3.8 ± 0.3†
IL-10, % CD3+ cells	1.4 ± 0.5	1.5 ± 0.3	4.6 ± 0.5*	3.8 ± 0.5†

Data are means ± SE.

^*Significant difference from ANG II-treated male ± SD.

^†Significant difference from ANG II + A-779 treatment; n = 5.